Business Wire

Legerity FastPost Helps Leading Life Insurer to Automate New Financial Reporting and Disclosures Process

Share

Aegon UK, a leading savings, protection and investment service provider has selected Legerity Limited’s FastPost IFRS 17 solution to help it transition to the new International Financial Reporting Standard (IFRS 17). The new standard takes effect from January 2022 and is one of the most significant changes to accounting in the insurance sector in years,

Legerity will provide Aegon UK with its third generation FastPost Accounting Rules and Sub-Ledger solution for implementation as an integrated part of its overall IFRS 17 accounting and reporting process.

David Wilson, IFRS 17 Programme Director at Aegon UK, comments, “IFRS 17 is a complex standard impacting multiple stakeholders including Actuarial, Finance and IT. There is no one size fits all solution for IFRS 17 so it is important that we selected best in class technology that can seamlessly integrate into our end to end financial reporting solution. After a detailed market and product evaluation process we have selected Legerity FastPost. We have been greatly impressed by the Legerity team and their FastPost accounting rules and sub-ledger technology.”

Legerity FastPost has also been selected by other Aegon regions for implementation as part of the Aegon Group’s IFRS 17 global programme.

Jeremy Wood, CEO and Founder of Legerity, adds “We are delighted to have entered into this agreement to be a key solution provider to Aegon’s future financial reporting. Aegon is a forward looking firm committed to market innovation and a digital future. It is great testament to our technology, team and achievements to have been selected by Aegon”.

Notes to Editors

About Aegon

• In the UK, Aegon offers retirement, workplace savings and protection solutions to well over three million customers and employs approximately 3,450 staff. More information: www.aegon.co.uk

• As an international life insurance, pensions and asset management group based in The Hague, Aegon has businesses in over twenty five markets in the Americas, Europe and Asia. Aegon companies employ over 28,000 people and have millions of customers across the globe. Further information: www.aegon.com

About Legerity

Legerity helps clients deliver complex accounting change. Legerity’s FastPost Accounting Rules platform provides a 3rd generation solution that meets the new IFRS 9, 15, 16 and 17 accounting standards in a fast and non-disruptive manner.

IFRS 17 is an opportunity to go beyond just compliance. Legerity FastPost standardises data across the enterprise to deliver real benefits: simplified processing, improved reporting, faster close, reduced cost and future-proof scalability.

Available as a SaaS cloud-based fully managed service, FastPost provides highly scalable and on demand performance, giving firms’ confidence that IFRS accounting data is available when required.

For further information please visit www.legerityfinancials.com

Contact information

Jeremy Wood
CEO – Legerity Limited
Jeremy.wood@legerityfinancials.com
Tel: +44 (0)203 871 2944
Mob: +44 (0)7775 681478

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria24.1.2020 06:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), as well as the ongoing Phase II (PVO-1A-202/204) extension studies. In both the Phase III and Phase II extension studies, palovarotene is dosed both chronically (daily) and episodically (during flare-ups). The decision to pause dosing patients in the trial is based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the prespecified interim analysis. The results of a futility analysis indicated that the Phase III FOP trial was unlikely to meet its primary efficacy endpoint (annualized change in new HO volume as compared with Natural History Studyi) upon completion. Despite the results of the prespecified interim analysis, signals of encouraging therapeutic activity w

Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos23.1.2020 20:56:00 CETPress release

Amazentis announces the debut of Timeline, a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland. Given the increase in the aging population globally -- according to a 2019 Deutsche Bank study, there are more people on Earth older than sixty five than younger than five for the first time -- it is imperative for consumers to take proactive measures to maintain a high quality of life, for as long as they live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005820/en/ (Photo: Business Wire) Timeline contains the proprietary nutrient Mitopure™, a highly pure form of Urolithin A. After a decade of rigorous research by leading scientists around the world, Mitopure has been shown to help counter age-associated cellular and muscular decline by revitalizing the mitochondria, the powerplants

Lionbridge Names Corinne Saunders as Managing Director, EMEA23.1.2020 18:00:00 CETPress release

Today, Lionbridge, a global leader in localization and data training services, announced that former Wolters Kluwer executive Corinne Saunders has joined the company as managing director of EMEA. Lionbridge currently has 51 offices in 26 countries around the world; Saunders will oversee EMEA sales, account management, and marketing operations. “Europe represents a large portion of our overall business and will continue to be a growth area for our AI and localization businesses. I am very happy that Corinne is coming onboard to lead our efforts across EMEA,” says Lionbridge Chief Executive Officer John Fennelly. “Throughout her career, she’s shown an exceptional ability for driving innovation and understanding customer needs.” While at Wolters Kluwer, Saunders served as chief executive officer for emerging and developing markets. Saunders will work from Brussels, Belgium. About Lionbridge Lionbridge partners with brands to break barriers and build bridges all over the world. For more th

President Bill Clinton to Keynote 2020 World Patient Safety, Science & Technology Summit23.1.2020 17:34:00 CETPress release

President Bill Clinton, the 42nd President of the United States, will be the closing keynote speaker at the Patient Safety Movement Foundation’s 2020 World Patient Safety, Science & Technology Summit. The 8th annual Summit will be held in Huntington Beach, California, beginning with a Pre-Summit Symposium on Thursday, March 5th. At the 2020 Summit, hospital leaders, medical and information technology innovators, patient advocates, policy makers and government officials collaborate and discuss best practices solutions to eliminate preventable patient deaths in hospitals around the world. The event is co-convened with the International Society for Quality in Health Care (ISQua), the American Society of Anesthesiologists and the European Society of Anaesthesiology. The 2020 Summit is scheduled for March 5 – 7th, 2020, at the Waterfront Beach Resort in Huntington Beach, California. For more information about the 2020 World Patient Safety, Science & Technology Summit, visit http://patientsa

Covantis initiative announces technology partner - ConsenSys23.1.2020 15:00:00 CETPress release

The founding members of the Covantis initiative, which aims to modernize global trade operations, have announced the selection of ConsenSys, a market-leading Ethereum blockchain technology company, as the lead technology partner to develop its transformative platform. “The founders set up a robust selection process, including a two week hackathon, to ensure that we chose the right technology partner to meet our industry’s needs,” said Stefano Rettore, independent advisor to the project. “ConsenSys presented prototypes that demonstrated excellence in its field and has a track record of using blockchain technology to digitize processes in the commodity trade finance industry. We are confident this partnership will allow us to build a first-class product, centered around unparalleled functionality, security and privacy.” ConsenSys will leverage its enterprise-ready blockchain solutions and services, including PegaSys Orchestrate, Kaleido and MythX to build the blockchain network on Ethere

PathoQuest’s Paris-based Facility Obtains GLP Certificate for the Company’s Biologics Genomic Quality Control Testing Service23.1.2020 13:00:00 CETPress release

PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to have a facility receive such a GLP certificate from the ANSM for advanced, Next Generation Sequencing viral safety testing (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005345/en/ (Graphic: Business Wire) Violaine Melen, PathoQuest’s Chief of Quality Assurance and Regulatory Affairs, stated “we are really proud of the achievement of this key regulatory milestone. Receiving this GLP certificate is the confirmation of the quality of our entire process, from receipt of a biological sample to report generation, inclusive of bioinformatics analysis a